BI 1701963

BI 1701963 is an investigational drug that blocks KRAS activation by binding to SOS1 proteins. The drug is thought to be effective in cancers with a KRAS mutation. It has been tested in clinical trials alone and in combination with adagrasib.^[1]^[2]^[3]

References[edit]

^ "Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)". www.cancer.gov. 23 June 2016. Retrieved 19 November 2023.
^ Johnson, M.L.; Gort, E.; Pant, S.; Lolkema, M.P.; Sebastian, M.; Scheffler, M.; Hwang, J.; Dünzinger, U.; Riemann, K.; Kitzing, T.; Jänne, P.A. (September 2021). "524P A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis". Annals of Oncology. 32: S591–S592. doi:10.1016/j.annonc.2021.08.1046.
^ Hofmann, Marco H.; Lu, Hengyu; Duenzinger, Ulrich; Gerlach, Daniel; Trapani, Francesca; Machado, Annette A.; Daniele, Joseph R.; Waizenegger, Irene; Gmachl, Michael; Rudolph, Dorothea; Vellano, Christopher P.; Marotti, Marcelo; Vucenovic, Vitomir; Heffernan, Timothy P.; Marszalek, Joseph R.; Petronczki, Mark P.; Kraut, Norbert (1 July 2021). "Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan". Cancer Research. 81 (13_Supplement): CT210–CT210. doi:10.1158/1538-7445.AM2021-CT210.

[1] "Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)". www.cancer.gov. 23 June 2016. Retrieved 19 November 2023.

[2] Johnson, M.L.; Gort, E.; Pant, S.; Lolkema, M.P.; Sebastian, M.; Scheffler, M.; Hwang, J.; Dünzinger, U.; Riemann, K.; Kitzing, T.; Jänne, P.A. (September 2021). "524P A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: A snapshot analysis". Annals of Oncology. 32: S591–S592. doi:10.1016/j.annonc.2021.08.1046.

[3] Hofmann, Marco H.; Lu, Hengyu; Duenzinger, Ulrich; Gerlach, Daniel; Trapani, Francesca; Machado, Annette A.; Daniele, Joseph R.; Waizenegger, Irene; Gmachl, Michael; Rudolph, Dorothea; Vellano, Christopher P.; Marotti, Marcelo; Vucenovic, Vitomir; Heffernan, Timothy P.; Marszalek, Joseph R.; Petronczki, Mark P.; Kraut, Norbert (1 July 2021). "Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan". Cancer Research. 81 (13_Supplement): CT210–CT210. doi:10.1158/1538-7445.AM2021-CT210.

[1]

[2]

[3]